PIK3CA Mutation is Associated with Poor Response to HER2-Targeted Therapy in Breast Cancer Patients
. 2022; 
PIK3CA Mutation is Associated with Poor Response to HER2-Targeted Therapy in Breast Cancer Patients
Cancer Research and Treatment. 2023;55(2):531-541
The predictive and prognostic role of phosphatase phosphoinositol-3 (PI3) kinase (PIK3CA) mutation in HER2-positive breast cancer receiving HER2-targeted therapy: a meta-analysis
Breast Cancer Research and Treatment. 2015;152(3):463-476
PIK3CA mutation: changing the paradigm of HR+ HER2-negative metastatic breast cancer therapy. Review of the Novartis Pharma satellite symposium, held as part of a virtual forum dedicated to the diagnosis and treatment of patients with hormone-dependent HER2-negative advanced breast cancer with a PIK3CA gene mutation. April 23, 2021
Journal of Modern Oncology. 2021;23(2):269-274
Noncardiac Toxicity of HER2-Targeted Therapy
Her2-Positive Breast Cancer. 2019;171-178
HER2-positive breast cancer: neoadjuvant and adjuvant therapy
Handbook of HER2-Targeted Agents in Breast Cancer. 2016;29-49
HER2-Positive Breast Cancer: Adjuvant and Neoadjuvant Therapy
Handbook of HER2-targeted agents in breast cancer. 2013;25-42
Breast cancer organoids model treatment response of HER2 targeted therapy in HER2-mutant breast cancer
Annals of Oncology. 2019;30:v768-v769
Combined Antiangiogenic and Mammalian Target of Rapamycin Inhibitor Targeted Therapy in Metaplastic Breast Cancer Harboring aPIK3CAMutation
Journal of Breast Cancer. 2014;17(3):287
Molecular mechanisms of resistance to HER2-targeted therapy
Breast Cancer Research. 2009;11(S1):